The Crow Verdict: I buy my and my family''s medicines from hospital''s pharmacy or local retailers (unorganized market). Sometimes I buy from Wellness Forever because it stays open 24/7. Not once have I bought from MedPlus, so I don''t have any personal bias on this company unlike HUL, ITC, and Marico (only considering the FMCG section of MedPlus).
Having said that, I have doubts about the sustainability of such branded pharmacies. The #1 Apollo and heavy competitor Wellness Forever have good-looking pharmacies but I still prefer local retailers over them. It''s not like I have any loyalty to them. Sure, the industry may be tappable but I don''t like to suspend 15k on this bet that I don''t have full confidence in.
That brings me to this issue offer, which because of its first-mover advantage has been priced aggressively. At a P/E of ~88 and P/B of ~7, this is steep valuation. Nothing is left on the table so I can''t believe in the <30% GMP of 230 (which started going down from 320 last week). The Tarsons story is still fresh in our minds. Plus, the 2 Rs FV and high promoter pledging for a potential longterm play is concerning.
This is a risky bet and I recommend applying with caution. Retail allotment might be 1 in 3 app wise so don''t apply more than 2 lots. Play with a single lot if allotted and exit immediately on listing regardless of gains/loss to take advantage of the pharma/pandemic fancy. Wait for QIB and overall to go beyond 3X and apply. Otherwise, skip. I have applied 1 lot via HDFC ASBA. Will decide on the 2nd retail after 3 PM.
Red flags - 5 out of 11. Keep crowing!
Always in restraint of Mrs. Crow.